Not all laboratories can manipulate viruses such as SARS-CoV-2, as a high biological containment level is required.
An Italian company based in a Science and Technology Park, has access to a newly built Biosafety Level 3 (BSL3) facility (50 m2 lab space) where new coronavirus expansion can be performed and infected cell cultures can be maintained. The BSL3 facility has been validated and certified for ISO requirements by leading company with 40 years’ experience in building clean rooms and high containment biosafety laboratories.
The Company’s main mission consists in the development of drug composites directed to overcome the underlying cellular perturbations common to viral diseases and cancers, especially as regards:
• Dysregulation of cellular transcription;
• Uncontrolled cell proliferation.
Its key operational fields are viral diseases and oncology. The Company is developing compounds against viral infections such as Hepatitis B, Human Papillomavirus, Epstein-Barr virus. In addition to this, given its unique mechanism of action, the company is running a program in the field of oncology. The Italian company is raising high interest from various pharmaceutical companies because of the research programs.
The Italian company has now access to different SARS-Cov-2 strains and having background in infectious diseases, high experience in drug combinations and drug development in general, was able to develop robust methodologies to test drugs (or other materials, such as antibodies) for anti-coronavirus activity. In detail:
- Testing efficacy of drugs against SARS-CoV-2;
- Testing cytotoxicity of drugs.
The company is interested in entering in contact other pharma companies that might be interested in such a know how, through commercial agreements with technical assistance (strong background of the research team can give specific technical advice).
Company can also be interested in technical o research and cooperation agreements with other companies or research organisations interested in submitting proposals under Horizon 2020 or other research programmes.